2 results
Approved WMOPending
The primary objective of this clinical performance study is to evaluate the effectiveness of the B7-H4 (A57.1) CTA in identifying B7-H4 positive (B7-H4 membrane staining at any intensity in >=25% tumor cells) ovarian, endometrial, biliary…
Approved WMORecruiting
The purpose of this study is to assess whether a new combination treatment (Savolitinib and Durvalumab) is better than standard treatment sunitinib in MET-driven PRCC. The study will also assess the contribution of one part of the combination (…